Year: 2003
Type: article
Abstract: Adrenaline (epinephrine) is the recommended first line treatment for patients with anaphylaxis.This review discusses the safety and efficacy of adrenaline in the treatment of anaphylaxis in the light of currently available evidence.A pragmatic approach to use of adrenaline auto-injectors is suggested.Anaphylaxis is the clinical syndrome representing the most severe systemic allergic reactions.Mediator release results in smooth muscle contraction, vasodilation, increased vascular permeability, and activation of vagal pathways, leading to the classic features of anaphylaxis, including urticaria and angioedema, bronchoconstriction and hypotension.Owing to the nature of anaphylaxis there are few controlled clinical trials, and therapeutic recommendations are based on clinical observation and animal models.We look at the current evidence for the use of adrenaline (epinephrine) in anaphylaxis, including its safety and route and timing of administration.We also discuss adrenaline auto-injectors and their role in patients with anaphylaxis. MethodsWe searched Medline using the key words adrenaline, anaphylaxis, epinephrine, and Epipen, and articles from the authors' personal collection.When necessary we accessed cross references and related articles.Evidence has been graded, where possible (see bmj.com).Only studies with clinical outcomes have been classified (see table on bmj.com); those showing in vitro improvements have not been graded.
Source: BMJ
Authors: Andrew P C McLean-Tooke, Claire A Bethune, Ann C Fay, Gavin P Spickett
Institution: Royal Victoria Infirmary
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2002375853
